NCT03013218 2025-08-01
A Study of Evorpacept (ALX148) in Patients With Advanced Solid Tumors and Lymphoma (ASPEN-01)
ALX Oncology Inc.
Phase 1 Completed
ALX Oncology Inc.
Eli Lilly and Company
Progen Pharmaceuticals
Teva Branded Pharmaceutical Products R&D, Inc.